Table 1 Summary of included studies on the magnitude of Option B plus antiretroviral therapy adherence and associated factors, 2019
Author | Year of publication | Country | Study design | sample size | Prevalence (95%CI) |
|---|---|---|---|---|---|
Zacharius et al. [15] | 2019 | Tanzania | Cross-sectional | 305 | 45.90 (40.31,51.49) |
Tsegaye et al. [12] | 2016 | Ethiopia | Cross-sectional | 191 | 87.43 (82.73,92.14) |
Tesfaye et al. [16] | 2019 | Ethiopia | Cross-sectional | 290 | 81.38 (76.90,85.86) |
Shibabaw et al. [23] | 2018 | Ethiopia | Cross-sectional | 41 | 95.12 (88.53,101.72) |
Mihratu et al. [24] | 2018 | Ethiopia | Cross-sectional | 304 | 79.61 (75.08,84.13) |
Lodebo et al. [25] | 2017 | Ethiopia | Cross-sectional | 215 | 83.72 (78,79,88.66) |
Ebuy et al. [13] | 2015 | Ethiopia | Cross-sectional | 277 | 87.00 (83,04,90.96) |
Schnack et al. [26] | 2016 | Uganda | Cross-sectional | 124 | 95.97 (92.51,99.43) |
Okawa et al. [27] | 2015 | Zambia | Cohort study | 321 | 82.55 (78.40,86.71) |
Haas et al. [28] | 2016 | Malawi | Cohort Study | 765 | 30.07 (26.82,33.31) |
Mwalumuli EO [29] | 2017 | Tanzania | Cross-sectional | 338 | 58.88 (53.63,64,12) |
Erlwanger et al. [30] | 2017 | Zimbabwe | Cohort study | 1150 | 31.91 (29.22,34.61) |
Yazine D et al. [31] | 2017 | Ethiopia | Cross-sectional | 269 | 75.09 (69.92,80.26) |
Mihretu T et al. [7] | 2019 | Ethiopia | Cross-sectional | 293 | 82.59 (78.25,86.94) |
Over all with weights from random effect | 71.88 (58.54,85.23) | ||||